 A double-blind, single centre comparative study in which fourteen groups of 40 male and female adults 18 years of age will be randomly allocated to receive 1.7, 5, 15 or 45 μg quantities of whole virion WV, Aluminium -adjuvanted WVAl-WV, and virosomal V influenza AHong Kong107399 H9N2 vaccines by intramuscular injection into the deltoid muscle; or 5 or 15microg WV vaccine administered by intradermal injection. A second dose of the same vaccine containing the same quantity of antigen as in the first dose will be administered 21 days later. Subjects will be observed for local and systemic reactions for 30 minutes after each immunisation day 0 and 21, and will be monitored for any reactions and other adverse events for 7 days after immunisation. Blood for immunogenicity studies will be obtained at day 0 pre-immunisation, day-21 4 days, and at day-42 i.e., 21 4 days after the second immunization. Immunogenicity will be evaluated by haemagglutination inhibition, virus neutralization,, single radial haemolysis, neuraminidase inhibition and cellular mediated responses in a subset of 5-10 subjects from each group. 